Table 3. Different EGFR mutations and response to EGFR TKIs.
| Case | Mutation | Mutated exons | TKIs | Line | Response | RFS# (months) | OS# (months) |
|---|---|---|---|---|---|---|---|
| 1 | G719S+L861Q | 18, 21 | Gefitinib | 1 | PR | 65.0 | 68.0+ |
| 6 | V689L+L858R | 18, 21 | Erlotinib | 3 | PR | 20.7 | 29.4+ |
| 18 | E709K+G719C | 18 | Gefitinib | 2 | PR | 14.8+ | 14.8+ |
| 21 | G724S+S768I | 18, 20 | Erlotinib | 2 | SD | 24.2+ | 24.2+ |
| 23 | E709K+L858R | 18, 21 | Gefitinib | 1 | PR | 37.5+ | 37.5+ |
#RFS and OS were calculated since taking TKIs.
TKIs, tyrosine kinase inhibitors; RFS, recurrence-free survival; OS, overall survival; PR, partial response; SD, stable disease.